A DNA Data Deluge Confronts Researchers

NEEDHAM, MA, Apr 17 (MARKET WIRE) --
Next-generation DNA sequencers are already generating enough data to prompt
researchers to drop traditional methods of data storage and management and
develop new ways of handling the torrents of information, according to Bio-IT
World magazine.

In the April cover story, "The DNA Data Deluge," Bio-IT World
editor-in-chief,
Kevin Davies, describes in detail how sequencer vendors and users are working
full-bore to develop data management solutions for the machines that produce
terabytes of information. For instance, the first HeliScope sequencer delivered
by Helicos BioSciences comes complete with a 32-CPU server stack and 24
terabytes of storage -- and that's just enough storage for two full runs.

Another example of the paradigm change, according to the article, is at
theBroad Institute, where a fleet of Applied Biosystems (ABI) 3730 sequencers is
being
supplanted by 20 Illumina instruments producing 20 billion bases of sequence a
week and climbing.

Add to that picture similar outputs from ABI's new SOLiD sequencers and
454Life Sciences technology, and you see the daunting challenge facing users of
the data and those responsible for its movement and storage. In the article,
Davies explains how companies such as Geospiza, GenomeQuest, and BioTeam are
developing IT solutions to meet that challenge.

Also in the April 2008 issue of Bio-IT World

In another article in the April 2008 issue, Davies describes how a small
biopharmaceutical company in Cambridge, MA, Ensemble Discovery, is
commercializing DNA programmable chemistry, developed by Harvard's (and Howard
Hughes Medical Institute's) David Liu, to build large collections of
macrocyclic compounds called "Ensemblins" that may provide new leads against a
variety of targets.

Other highlights of this issue:

-- Amgen's successful advances in cancer diagnostics
-- Google enters the field of enterprise searching
-- GeneGo launches its first in a series of disease-specific software
tools, this one for cystic fibrosis
-- An MIT study analyzes the global aspects of clinical trials
-- Federal agencies start a National Toxicology Program aimed at reducing
reliance on animal testing

About Bio-IT World

Bio-IT World (www.bio-itworld.com), the flagship publication of Cambridge
Healthtech Institute (CHI), is the leading source of news on technology
andstrategic innovation in drug discovery, development, and clinical trials.
Bio-IT
World explores the tools and results of predictive biology as the industry
adapts to the new world of personalized medicine. Bio-IT World has won 34
national and regional awards, more than any other magazine covering the life
sciences industry. CHI offers a suite of published resources through a new
division
-- Cambridge Healthtech Media Group -- that includes Bio-IT World magazine,
numerous topic-specific eNewsletters, white papers, webcasts, podcasts,
conferences, and the Bio-IT World Best Practices Awards. The magazine is based
in
Needham, MA.

About Cambridge Healthtech Institute

Founded in 1992, Cambridge Healthtech Institute (www.healthtech.com) is
theindustry leader offering the preeminent source of information to the leading
researchers and business experts from top pharmaceutical, biotech, and academic
organizations. Delivering an assortment of resources such as events,
reports, publications, and eNewsletters, CHI's portfolio of products
includes Cambridge Healthtech Institute Events, Pharmaceutical Strategy Series,
Insight
Pharma Reports, Marketing Services, and Cambridge Healthtech Media Group.

Contact:
Kevin Davies
(Editor-in-Chief, Bio-IT World)
Email Contact
781-972-1341

Copyright 2008, Market Wire, All rights reserved.

-0-